There are 2789 resources available
1197P - First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN
Presenter: Qing Zhou
Session: ePoster Display
1198P - Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)
Presenter: Claudia Parisi
Session: ePoster Display
1199P - Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: ePoster Display
1164P - Whole-course management of surgical NSCLC patients based on ctDNA detection: Neo-adjuvant treatment efficacy prediction and postoperative recurrence monitoring
Presenter: Dongsheng Yue
Session: ePoster Display
1165P - Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial
Presenter: Parneet Cheema
Session: ePoster Display
1166P - Determinants of clinical and pathological stage discordance in resected NSCLC patients: A retrospective observational cohort study
Presenter: Evangeline Samuel
Session: ePoster Display
1167P - DIO2 is implicated in the antitumor effect of the lung embryonic stem cell conditioned medium and impacts prognosis in non-small cell lung cancer
Presenter: Jordi Canals
Session: ePoster Display
1050P - Outcome and impact of immune related adverse events in patients with advanced melanoma treated with checkpoint inhibitors
Presenter: Arkhjamil Angeles
Session: ePoster Display
1051P - Impacts of skeletal muscle on survival in resected stage III malignant melanoma
Presenter: Susie Youn
Session: ePoster Display
1052P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: ePoster Display